Hammerl D - Search Results

1

Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1^st-line tamoxifen therapy in breast cancer.

Uhr K, Sieuwerts AM, de Weerd V, Smid M, Hammerl D, Foekens JA, Martens JWM. Uhr K, et al. Among authors: hammerl d. Sci Rep. 2018 Jun 25;8(1):9657. doi: 10.1038/s41598-018-27987-w. Sci Rep. 2018. PMID: 29941867 Free PMC article.

2

Breast cancer genomics and immuno-oncological markers to guide immune therapies.

Hammerl D, Smid M, Timmermans AM, Sleijfer S, Martens JWM, Debets R. Hammerl D, et al. Semin Cancer Biol. 2018 Oct;52(Pt 2):178-188. doi: 10.1016/j.semcancer.2017.11.003. Epub 2017 Nov 6. Semin Cancer Biol. 2018. PMID: 29104025 Free article. Review.

3

Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies.

Hammerl D, Rieder D, Martens JWM, Trajanoski Z, Debets R. Hammerl D, et al. Trends Immunol. 2018 Nov;39(11):921-936. doi: 10.1016/j.it.2018.09.004. Epub 2018 Oct 9. Trends Immunol. 2018. PMID: 30309702 Review.

4

Clonality, Antigen Recognition, and Suppression of CD8⁺ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes.

Hammerl D, Massink MPG, Smid M, van Deurzen CHM, Meijers-Heijboer HEJ, Waisfisz Q, Debets R, Martens JWM. Hammerl D, et al. Clin Cancer Res. 2020 Jan 15;26(2):505-517. doi: 10.1158/1078-0432.CCR-19-0285. Epub 2019 Oct 24. Clin Cancer Res. 2020. PMID: 31649042

5

Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells.

Agahozo MC, Smid M, van Marion R, Hammerl D, van den Bosch TPP, Timmermans MAM, Heijerman CJ, Westenend PJ, Debets R, Martens JWM, van Deurzen CHM. Agahozo MC, et al. Among authors: hammerl d. Biology (Basel). 2021 Aug 12;10(8):768. doi: 10.3390/biology10080768. Biology (Basel). 2021. PMID: 34440000 Free PMC article.

6

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer.

Hammerl D, Martens JWM, Timmermans M, Smid M, Trapman-Jansen AM, Foekens R, Isaeva OI, Voorwerk L, Balcioglu HE, Wijers R, Nederlof I, Salgado R, Horlings H, Kok M, Debets R. Hammerl D, et al. Nat Commun. 2021 Sep 27;12(1):5668. doi: 10.1038/s41467-021-25962-0. Nat Commun. 2021. PMID: 34580291 Free PMC article.

7

Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?

Agahozo MC, Hammerl D, Debets R, Kok M, van Deurzen CHM. Agahozo MC, et al. Among authors: hammerl d. Mod Pathol. 2018 Jul;31(7):1012-1025. doi: 10.1038/s41379-018-0030-x. Epub 2018 Feb 20. Mod Pathol. 2018. PMID: 29463884 Free article. Review.

8

V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma.

Mutsaers P, Balcioglu HE, Kuiper R, Hammerl D, Wijers R, van Duin M, van der Holt B, Broijl A, Gregory W, Zweegman S, Sonneveld P, Debets R. Mutsaers P, et al. Among authors: hammerl d. Cancers (Basel). 2021 May 6;13(9):2219. doi: 10.3390/cancers13092219. Cancers (Basel). 2021. PMID: 34066382 Free PMC article.

9

Cancer germline antigens and tumor-agnostic CD8⁺ T cell evasion.

Kortleve D, Coelho RML, Hammerl D, Debets R. Kortleve D, et al. Among authors: hammerl d. Trends Immunol. 2022 May;43(5):391-403. doi: 10.1016/j.it.2022.03.006. Epub 2022 Apr 10. Trends Immunol. 2022. PMID: 35414484 Free article. Review.

10

Gene Engineering T Cells with T-Cell Receptor for Adoptive Therapy.

Kortleve D, van Brakel M, Wijers R, Debets R, Hammerl D. Kortleve D, et al. Among authors: hammerl d. Methods Mol Biol. 2022;2453:209-229. doi: 10.1007/978-1-0716-2115-8_13. Methods Mol Biol. 2022. PMID: 35622329 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters